Abstract 4703: The inhibitor of apoptosis protein (IAP) antagonist Debio 1143 enhances the immune response to anti-PD1/L1 inhibitors in vitro and in vivo
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-4703
Abstract: Background: Debio 1143 is an oral antagonist of IAPs, currently in clinical development, which sensitizes tumor cells to radiation- or chemotherapy-induced apoptosis. IAPs inhibitors modulate NF-κB signaling and drive the expression of genes relevant for… read more here.
Keywords: inhibitors vitro; anti; debio 1143; antagonist ... See more keywords
The IAP Antagonist Debio 1143 Enhances Chemoradiotherapy in HNSCC.
Sign Up to like & getrecommendations! Published in 2020 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-rw2020-116
Abstract: Debio 1143 plus chemoradiotherapy improved head and neck squamous cell carcinoma disease control. read more here.
Keywords: antagonist debio; 1143 enhances; debio; chemoradiotherapy ... See more keywords